12 results about "Human herpes virus" patented technology

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

This fatigue estimation device (100) comprises: a fatigue estimation model (12) constructed in advance on the basis of data including a relationship between a physiological quantity outside an activity period of a person and the amount of human herpesvirus outside the activity period, the fatigue estimation model (12) being capable of outputting a fatigue degree estimated from the corresponding amount of human herpesvirus in response to an input of biometric information; a physiological quantity measurement unit (20) for measuring a physiological quantity of a subject (user (99)); and a fatigue estimation unit (10) for outputting the fatigue degree of the subject on the basis of the measured physiological quantity by using the fatigue estimation model (12).

The present invention relates to a multiplex gene detection system for viral and bacterial infection of the central nervous system, comprising forward and reverse primers for detecting enterovirus, human double echovirus, Mycobacterium tuberculosis, Listeria monocytogenes, Streptococcus pneumoniae, varicella zoster virus, mumps virus, cytomegalovirus, herpes simplex virus type 1, herpes simplex virus type 2, Neisseria meningitidis, Epstein-Barr virus, Streptococcus agalactiae, Haemophilus influenzae, human herpes virus type 6, Escherichia coli K1 and Japanese encephalitis virus, and the detection sample is cerebrospinal fluid. The multiplex gene detection product for viral and bacterial infection of the central nervous system of the present invention has high throughput, low cost, high sensitivity and good specificity, and is used for synchronous identification and semi-quantitative analysis of multiple viral and bacterial infections of the central nervous system.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

Human herpesviruses can infect barrier and immune cells of the intestines to cause microbiome dysbiosis and inflammation. Microbiome dysbiosis can affect the brain function, and inflammation can compromise the intestinal barrier and lead to microbial translocation. Embodiments may restrict herpesvirus activity and injury by 1) the oral administration of exosomes containing factors to inhibit viral activity and restore homeostasis, and 2) the oral administration of recombinant bacteria that produce exosomes containing factors to inhibit viral activity and restore homeostasis. Embodiments also measure HHV activity in stool by ELISA immunoassay of HHV proteins.

The invention discloses a primer combination for simultaneously detecting eight herpes viruses by a single tube, a PCR (Polymerase Chain Reaction) detection system and application, and relates to the technical field of herpes virus detection. Aiming at eight human herpes viruses, the invention provides a corresponding primer combination and an octuple PCR detection system, the detection sensitivity to single and mixed infection of the herpes viruses reaches 1 * 10 < 4 > copies (50 mu L system), non-specific amplification is avoided, and the eight human herpes viruses can be detected at the same time. When the system is used for detecting 30 cell samples, one EBV sample is detected to be positive, the rest EBV samples are detected to be negative, the result is consistent with the result obtained by using an EBV rapid visual detection system established in an earlier stage of a laboratory, and very high accuracy is achieved.

To provide compositions and methods for the inhibition of the infectivity of a herpesvirus.SOLUTION: A composition comprises: a) a CRISPR-associated (Cas) peptide or an isolated nucleic acid encoding the Cas peptide; and b) an isolated guide nucleic acid or an isolated nucleic acid encoding the guide nucleic acid, the guide nucleic acid comprising a nucleotide sequence substantially complementary to a target sequence in a herpesvirus genome.SELECTED DRAWING: Figure 1A-1

The invention discloses a kit for multi-typing detection of human herpes viruses HHV-1 to HHV-8, and the kit comprises a group of nucleic acid combination which comprises 9 pairs of RPA (recombinase polymerase amplification) primers which are respectively and specifically combined with target genes of HHV-1 to HHV-8 and an EC (exogenous internal control), wherein each pair of primers comprises a forward primer and a reverse primer; wherein the 5'ends of the reverse primers of all the 9 pairs of primers are marked with biotin; the 5'ends of forward primers of the HHV-1, the HHV-4 and the HHV-7 are marked with first haptens; the 5'end of the forward primer of the HHV-2, the HHV-5 and the HHV-8 is marked with a second hapten; the positive primers of the HHV-3 and the HHV-6 are marked with a third hapten at the 5'end; a fourth hapten is marked at the 5'end of the forward primer of the EC; the invention relates to an RPA (recombinase polymerase amplification) reaction buffer solution which comprises the following components in concentration: 40-60 mM of Tris-HCl, 80-140 mM of potassium acetate, 10-20 mM of magnesium acetate, 3-8% (w / v) of polyethylene glycol and 0.5-2.0 M of betaine. And a plurality of lateral chromatography test strips.

The invention discloses a human herpes virus quadruple RPA (recombinase polymerase amplification) detection system based on isothermal amplification and application of the human herpes virus quadruple RPA detection system, and relates to the technical field of multiple human herpes virus RPA detection. The quadruple RPA detection system for the human herpes virus provided by the invention comprises a group A detection primer combination or a group B detection primer combination, the group A detection primer combination comprises detection primer pairs for respectively detecting HSV-1, HSV-2, VZV and EBV, and the group B detection primer combination comprises detection primer pairs for respectively detecting HCMV, HHV-6, HHV-7 and HHV-8. The invention further provides a quadruple RPA detection method for the human herpes virus based on the system. The quadruple RPA detection system provided by the invention has the advantages that the detection time is greatly shortened, the detection sensitivity is high, the specificity is strong, the carrying is more convenient, the required equipment is simple, and greater convenience is provided for human herpes virus detection.

Provided herein are compositions comprising isolated T cells specific for one or more viral antigens derived from viruses such as adenovirus (ADV), cytomegalovirus (CMV), BK virus (BKV), Epstein-Barr virus (EBV), human herpes virus 6 (HHV6), John Cunningham virus (JC), or human immunodeficiency virus (HIV), methods for obtaining them, libraries including them, and uses thereof in treating viral infections.

The present invention relates to N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, processes for its manufacture and uses. In particular, the present invention relates to the use of the above-mentioned compound for the treatment of human herpes virus infections and for the preparation of a medicinal product comprising said compound. The present invention is in the field of antiviral active agents.

The invention relates to the field of treatment of human herpes virus related diseases, in particular to a keratin 10 fragment and application thereof. The invention discloses a keratin 10 fragment. The keratin 10 fragment is a fragment of which the amino acid sequence is shown in 400th-453rd sites in wild keratin 10; and b, is a variant of the fragment in a, and can inhibit EB virus replication and cell transformation. After the keratin 10 fragment is transfected into cells, the growth and proliferation of EB virus positive cells can be remarkably inhibited.